2010
VPREB1 Deletions Occur Independent of Lambda-Light Chain Rearrangement and Predict Worse Outcome In Pediatric Acute Lymphoblastic Leukemia (ALL)
Miles R, Downie J, Jahromi M, Joshi D, Rodic V, Muschen M, Yang J, Evans W, Meeker N, Trede N, Frazer J, Barnette P, Schiffman J. VPREB1 Deletions Occur Independent of Lambda-Light Chain Rearrangement and Predict Worse Outcome In Pediatric Acute Lymphoblastic Leukemia (ALL). Blood 2010, 116: 273. DOI: 10.1182/blood.v116.21.273.273.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaLight chain rearrangementB cellsResearch HospitalWorse outcomesSt. Jude Children's Research HospitalCopy number alterationsPediatric acute lymphoblastic leukemiaB-cell developmental genesWorse clinical outcomesClinical risk stratificationSorted B cellsV-J junctionUnderstanding of leukemogenesisHomozygous deletionM2 marrowChain rearrangementClinical outcomesRisk stratificationLymphoblastic leukemiaEnhancer deletionBlood leukocytesHealthy volunteersHispanic ethnicityB cells results
2009
The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug-Resistance in Chronic Myeloid Leukemia.
Klemm L, Duy C, Iacobucci I, von Levetzow G, Feldhahn N, Kim Y, Hofmann W, Jumaa H, Groffen J, Heisterkamp N, Martinelli G, Lieber M, Casellas R, Müschen M. The B Cell Mutator AID Promotes B Lymphoid Blast Crisis and Drug-Resistance in Chronic Myeloid Leukemia. Blood 2009, 114: 3274. DOI: 10.1182/blood.v114.22.3274.3274.Peer-Reviewed Original ResearchBCR-ABL1 mutationsChronic myeloid leukemiaLymphoid blast crisisB-lymphoid blast crisisBCR-ABL1 kinase domainImatinib resistanceCML cellsBCR-ABL1Gene copy number alterationsDrug resistanceLeukemia cellsOverall survivalMyeloid leukemiaBlast crisisFive-year overall survivalCopy number alterationsNOD/SCID miceMedian overall survivalTreatment of patientsExpression of CD19Imatinib-resistant clonesMechanisms of progressionKinase inhibitor imatinibPresence of imatinibConcentrations of imatinib